MEDICAL BREAKTHROUGHS 2020

NEW **DIABETES + BREAST CANCER + PROSTATE CANCER** HOPE **VISION LOSS + HEART DISEASE + LUNG DISEASE** FOR:

Saving Their **AND OURS**

Meet some of the courageous patients who have found promise in the latest medical breakthroughs By Sarah Mahoney

proved health care access for the most ments a modern reality.

YES, 2020 HAS been a dark time. The vulnerable among us, while manufacturcoronavirus crisis exposed plenty ers such as Ford and GM have shown that of cracks in our national health they can quickly retool to create medical care system, and we lost far too many of equipment, exposing an opportunity for our peers and loved ones to an out-of- all companies to explore. So let's take a control pandemic. But as we mourn the moment to recognize many of the recent losses of this past year, there's reason for breakthroughs in medical care—advances optimism, not just for an end to the cur- that may pave the way for a healthier, rent crisis, but for all of the innovations happier tomorrow for all of us-and to that have arrived in its wake. The growth celebrate the heroic men and women who in telemedicine and health apps has im- have helped to make these futuristic treat-



Treating **Diabetes** With **Islet-Cell** Transplants

OME MEDICAL breakthroughs come as lightning bolts, but Randi Fibus-Caster has been riding the slow-moving train of islet-cell transplants for an astonishing 15 years. For most of her life, Fibus-Caster was called a "brittle diabetic," which meant that her type 1 diabetes caused such severe swings in blood sugar levels that passing out was a frequent occurrence. "I used to wear a lot of silver bangles on my arm, so they could hear me when I fainted at work," she says.

But since she had her islet-cell transplant in 2005, followed by a bone-

> marrow transplant 10 days later and an

> additional islet-cell

transplant in 2010, that has all changed.

She's been free from

insulin injections

for 10 years, with a

blood sugar score

on the low side of

normal. And she

takes just two anti-

rejection medica-

tions per day-very

low for a transplant

patient. That has

made her a success

story of the exper-



Bariatric surgery can prevent diabetes in very obese people (BMI of 40-plus). Now data shows it may cause remission in type 2 diabetics with a BMI as low as 30, especially for those with early onset.

imental procedure, which continues to be a major focus at the University of Miami's Diabetes Research Institute.

Such transplants are used in other countries, and researchers are await-



ing approval from the Food and Drug Administration (FDA), which is evaluating trial results. "This is an area where the U.S. lags," says Jay Skyler, M.D., deputy director of clinical research at the institute.

One hurdle for these transplants is finding more sources of insulinproducing cells. Currently, they come from cadavers and are in short supply. "We're still limited by only 1,200 cadavers per year," he says. Researchers hope that embryonic or induced pluripotent stem cells will one day be

a source of insulin-producing cells, making the treatment available to both type 1 and type 2 diabetics.

Both of Fibus-Caster's 2005 transplants came from the same cadaver donor, and the 2010 procedure from another. Doctors attribute her exceptional recovery to a high tolerance of the required antirejection drugs, which can be an obstacle for many.

She can't wait for the day the procedure is cleared for widespread use. "I'm so happy this transplant has given me a second chance." \rightarrow

MEDICAL BREAKTHROUGHS 2020



BREAST CANCER BREAKTHROUGH

Aggressive multidisciplinary therapy to attack an especially dangerous early-stage tumor

FTER 24 YEARS of perfect mammograms, Cora Shird, 66, got the call that women dread: She should come in for a retest. The retest, in March 2018, led first to a sonogram, then a biopsy, then a diagnosis, then tears. Two of her five sisters had already had breast cancer, and she knew how scary it could be. "After I got the call, I went into my manager's office, and we went down in the chapel, and I prayed," she says.

Adding to the fear, Shird discovered she had a type of cancer known as HER2+/ER+. About a quarter of all breast cancers are HER2+; these tumors have higher levels of a protein

called human epidermal growth factor receptor 2, which tends to make them grow and spread faster than other breast cancers.

Researchers had been studying this cancer subtype and had developed new treatment approaches, including an aggressive multidisciplinary therapy that was first proven beneficial in later stages of breast cancer. "Several treatments are now available to women with advanced breast cancer, and some are expected to also be incorporated in the early setting, including new treatments that target HER2," explains Vered Stearns, M.D., director of the women's malignancies program at the Kimmel Cancer Cen-

ter at Johns Hopkins University in Baltimore, which is where Shird was being treated.

First, Shird got a lumpectomy, with doctors removing three lymph nodes as well as the tumor. Next came 20 sessions of chemotherapy, followed by 15 rounds of radiation. "The first session was the worst, and



There are several breast cancer treatments that are generating

optimism. > New studies find that aromatase inhibitors (which reduce

estrogen), currently used to prevent recurrence, may prevent breast cancer from developing in the first place. > An immunotherapy drug, atezolizumab, is being tested in combination with the chemotherapy drug nab paclitaxel, potentially

creating a new line of treatment for difficult-to-treat "triple negative" cancers.

classes-even something called "sound meditation"-along with tai chi and walking. Today her cancer is in remission. Shird continues to take one medication daily, anastrozole, which reduces the risk of her breast cancer coming back. Her doctors expect her to be on this

drug for between

I was determined

that chemo wasn't

taking me down like

that," Shird says. So

she began taking

better care of her-

self, looking for

ways to build up her

immune system, in-

cluding meditation

five and 10 years. Shird, who has since retired from her job as a clinical technician, couldn't be more grateful, despite ongoing struggles with lymphedema, a common but

painful complication of lymph node removal that required physical therapy. "I just leaned into my faith," she says. "My three daughters gave me such strength and support. I even did a mission trip down to Jamaica. And when I lost my hair, I decided to be the baddest chick with a bald head."



PROSTATE CANCER BREAKTHROUGH

An experimental drug combo that controls hormones linked to prostate cancer progression

N 2016, John Hammel developed intense back pain, and an MRI revealed tragic news. He had late-stage prostate cancer that had already begun to spread through his body. "Because I'm a physician, I knew how devastating the diagnosis was. I was despondent-I didn't think I'd live a year." When his

oncologist told him real treatment was available-"treatment, not just palliative care"-he was skeptical. Then he met someone who had a similar case but was symptom-free for three years. He allowed himself to be hopeful.

At his oncologist's urging, Hammel joined a clinical trial led by Christopher Sweeney, M.D., at Dana-Farber





Cancer Institute in Boston. Because testosterone and other male hormones can fuel the growth of cancer cells, much research focuses on ways to either suppress the production of hormones or stop cells from receiving them. Sweeney's study did both, combining enzalutamide, an oral drug that blocks hormone reception, with testosterone-suppressing medication. The FDA-approved treatment may raise three-year survival rates by as much as 80 percent.

Hammel, a psychiatrist, was living in Vermont and continued working

throughout the trial, making regular trips to Boston for treatment. "I watched my PSA [a protein created by the prostate that goes up when the organ is diseased] drop from 2,000 to 450 to four and then to undetectable for six months-that's where it is now."

For Hammel. who says there is now no progression of his cancer, the trial has helped him start living, instead



Bv fusing a molecule that binds to a prostate-specific protein, scientists can spot tiny clusters of cancer in PET scansleading to earlier detection of recurrences than were possible with conventional imaging.

of focusing on his prognosis. When he and his wife found out one of their daughters was pregnant with their first grandchild, "that changed everything. We knew we wanted to be a part of the baby's life and part of my daughter's life more than we were."

So he found a new job in Seattle, and the couple moved west. Besides spending time with their grandchild, they bought a sailboat, reigniting an old love of cruising. "We had put our lives on hold and kept working in three-month intervals," he says. "But we are so fortunate that I've had this sustained response that we just decided to do what we want. If the tumor starts to win out again, we'll deal with it." \rightarrow

🖶 MEDICAL BREAKTHROUGHS 2020





VISION LOSS BREAKTHROUGH

Retinal implants to restore sight impaired by age-related macular degeneration (AMD)

ANNA KUEHL was scared. Ever since a diagnosis of dry macular degeneration in her late 40s–vounger than most patients-she had been monitoring her sight, using a special tool known as an Amsler grid. One day a large black area appeared in her left eve, and she went back to her doctors at the University of Southern California for help. There she discovered that a team of researchers were working on a promising treatment for her condition that involved stem cell-based implants. Even as she began taking the required immune-suppressant medication leading up to the surgery, she says, "I wasn't scared anymore. I was looking forward to it."

Surgeons implanted the tiny device-about the size of a human red blood cell-into the retinas of 15 patients, including Kuehl. Now that

some participants have passed the key one-year mark with improving vision, the procedure has cleared the way for A refillable

a larger clinical trial. eve implant The treatment can deliver the AMD drug uses an ultrathin ranibizumab, layer of specialized eliminating retinal cells to slow the need the progress of dry for monthly AMD. In some cas- injections. es the procedure

HORIZON

actually improves vision. That's what happened to Kuehl. She can now read her watch and see her entire face in the mirror. "Shortly after the surgery, I turned to my husband while we were watching TV and said, 'I can see all their faces!" Doctors say FDA approval is about five years away.



Radiation therapy to reprogram deadly heart arrhythmias

HEN BOB Bartlett collapsed during an exercise class in 2007, fast-acting paramedics saved his life. But the event led him down a complicated road of heart procedures and surgeries, an implanted defibrillator and debilitating medication. And he was burdened by the constant knowledge that he could drop dead at any moment from his fast and abnormal heart rate, a condition called ventricular tachycardia (VT).

"Once you know the feeling," Bartlett says, "you know that if it continues, you'll fall like a tree. And you know vou might die."

The attacks—which trigger the defibrillator to begin shocking the heart back into proper rhythm-can occur multiple times a year. "It feels kind of like a locker-room punch to the chest," he says of his VT attacks. Like Bartlett, many patients develop post-traumatic stress disorder from repeatedly having their heart shocked back into rhythm. And when his arrhythmia drug caused intensely painful neuropathy in his feet, he was ready to give up. "I realized that if this became the new normal. I wasn't sure I could live with it."

Then Bartlett learned about experimental work happening at Barnes-Jewish Hospital in St. Louis, where Washington University School of Medicine physicians were using radiation to ablate damaged heart tissue. The procedure remains investigational, so insurance may not cover it.

Diagnostics took a week as doctors mapped out the faulty areas of Bartlett's heart, but the actual procedure "took less time than

> the Chopin sonata he had on his

> earphones," says Clifford Robinson,

> M.D., professor of

radiation oncology

at Washington Uni-

versity, a co-pioneer

of the technique.

Unlike a typical ab-

lation, which can

take six hours or

more, the procedure

Doctors have now


performed it on a

is noninvasive.



In a study of 420.000 **Apple Watch** users who wore an electrocardiogram patch, the smartwatch accurately warned about atrial fibrillation in more than onethird of the

number of people. participants. One, a patient in her 80s, died within one month. from causes that may have been unrelated to the surgery. The other patients, who had experienced numerous VT episodes in the weeks before the procedure, have found that their incidents have decreased measurably, and in some cases have stopped altogether. Bartlett's are virtually nonexistentand so is his sense of dread.



"I felt the difference the instant I woke up." —Jim Hogan, 77, New York

LUNG DISEASE A F

JIM HOGAN'S chronic obstructive pulmonary disease (COPD) was getting worse, making it hard to finish his weekly golf games-or even walk down the driveway. Lucky for him, his

golf partner, a doctor, came across a journal article about Zephyr, a lung valve that was generating medical buzz in Europe.

When the FDA cleared Zephyr for use in the U.S. in 2018, Hogan lobbied to get insurance coverage for the procedure, traveling to Temple University Hospital in Philadelphia, the first U.S. center to use patients.

Nuvaira is a radiofrequency ablation that disrupts nerve signals and dilates the airways. In trials it reduced COPD flare-ups in



A tiny valve implant that boosts breathing by helping damaged lungs work more efficiently



the valve to treat severe emphysema. After a few hurdles—his insurance company considered it investigational, and he had to appeal—he had the valve implanted in April 2019.

It's a serious procedure, with a device the size of a pencil eraser inserted via a bronchoscope. The one-way valve blocks air from invading the damaged part of the lungs, where it can get trapped and hinder breathing.

"The instant I woke up from anesthesia, I felt the difference," he says.

"It took 20 years to develop and gain approval for a treatment," says Gerard J. Criner, M.D., director of the Temple Lung Center, where Hogan had his procedure. "It's less invasive than other treatments. It costs less. And it improves exercise function and quality of life." ■